Ethereum has reached a milestone with about 35% of its total supply—over 43 million ETH—now staked, reducing the liquid supply available for trading. Despite this tightening supply, Ethereum's price recently fell below $2,400 due to weak demand influenced by regulatory uncertainty and ETF outflows. The high staking participation means Ethereum could be more sensitive to future demand increases, potentially pushing prices back toward $2,600 or higher if buying interest strengthens. However, without stronger demand, the price may remain range-bound despite record staking levels.
Ethereum staking levels provide context for cryptocurrency market activity on Pluang as of Sep 17, 2026 21:23 WIB. Of 50 major cryptocurrencies priced, 46 rose while only 3 fell. Notably, Balancer (BAL) increased by 11.14% to Rp16.297 with a typical hold time of 85 days, Bitcoin Cash (BCH) rose 11.03% to Rp4.268.666 with 78% buy orders and a 68-day hold, and SushiSwap (SUSHI) gained 9.61% to Rp3.933 with 100% buy orders and a 101-day hold time, contrasting with Ethereum’s recent price dip below $2,400 despite high staking participation.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
